AVEO AVEO Pharmaceuticals Inc.

0.72
0  0%
Previous Close 0.72
Open
Price To Book -6.03
Market Cap 116,246,785
Shares 160,739,471
Volume 1,385
Short Ratio
Av. Daily Volume 2,983,557

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced December 7, 2017.
Ficlatuzumab and cetuximab
Head and neck squamous cell carcinoma (HNSCC)
Phase 2 data at ESMO 2018 noted 56% ORR.
Tivozanib + Opdivo
Renal cell cancer (RCC)
Announced September 12, 2016 that its Phase 2 trial has been discontinued
Ficlatuzumab
EGFR-mutated Non-small cell lung cancer (NSCLC)
Noted January 31, 2019 that FDA recommended against filing an NDA with current OS data. Additional interim OS analysis due August 2019 with further OS data 4Q 2019.
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer
Phase 1b poster presented at AACR April 1, 2019. 9/17 CRs.
Ficlatuzumab and cytarabine
Acute myeloid leukemia (AML)

Latest News

  1. AVEO (AVEO) Down 19.9% Since Last Earnings Report: Can It Rebound?
  2. AVEO Oncology to Present at the 2019 BIO International Convention
  3. Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
  4. AVEO Oncology Announces Presentations at the 2019 ASCO Annual Meeting
  5. AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark
  6. AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Tops Revenue Estimates
  7. AVEO: 1Q Earnings Snapshot
  8. AVEO Reports First Quarter 2019 Financial Results and Provides Business Update
  9. AVEO Pharmaceuticals (AVEO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
  10. AVEO Pharmaceuticals (AVEO) Dips More Than Broader Markets: What You Should Know
  11. AVEO Oncology to Participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit
  12. AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up?
  13. FRIDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  14. APRIL 26 DEADLINE: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AVEO Pharmaceuticals, Inc. (AVEO) and Encourages AVEO Investors Who Suffered Losses Exceeding $100,000 to Contact the Firm
  15. CLASS ACTION UPDATE for AVEO, AAPL and S: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  16. FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  17. CLASS ACTION UPDATE for CORT, AVEO, NIO and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  18. Final Deadline DPLO & AVEO Bronstein, Gewirtz & Grossman, LLC
  19. FRIDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm